Dana A. Kennedy

6.3k total citations · 3 hit papers
50 papers, 4.5k citations indexed

About

Dana A. Kennedy is a scholar working on Pathology and Forensic Medicine, Oncology and Dermatology. According to data from OpenAlex, Dana A. Kennedy has authored 50 papers receiving a total of 4.5k indexed citations (citations by other indexed papers that have themselves been cited), including 37 papers in Pathology and Forensic Medicine, 31 papers in Oncology and 18 papers in Dermatology. Recurrent topics in Dana A. Kennedy's work include Lymphoma Diagnosis and Treatment (36 papers), Cutaneous lymphoproliferative disorders research (18 papers) and CAR-T cell therapy research (14 papers). Dana A. Kennedy is often cited by papers focused on Lymphoma Diagnosis and Treatment (36 papers), Cutaneous lymphoproliferative disorders research (18 papers) and CAR-T cell therapy research (14 papers). Dana A. Kennedy collaborates with scholars based in United States, United Kingdom and France. Dana A. Kennedy's co-authors include Nancy L. Bartlett, Eric L. Sievers, Andres Forero‐Torres, Anas Younes, Joseph D. Rosenblatt, John P. Leonard, Ranjana H. Advani, Carmel M. Lynch, Joseph M. Connors and Radhakrishnan Ramchandren and has published in prestigious journals such as New England Journal of Medicine, The Lancet and Journal of Clinical Oncology.

In The Last Decade

Dana A. Kennedy

48 papers receiving 4.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Results of a Pivotal Phase II Study of Brentuximab Vedotin for Patients With Relapsed or Refractory Hodgkin's Lymphoma

2012 1.0k citations Anas Younes, Ajay K. Gopal et al. Journal of Clinical Oncology profile →
Brentuximab Vedotin (SGN-35) for Relapsed CD30-Positive Lymphomas

2010 963 citations Anas Younes, Nancy L. Bartlett et al. New England Journal of Medicine profile →
Brentuximab Vedotin (SGN-35) in Patients With Relapsed or Refractory Systemic Anaplastic Large-Cell Lymphoma: Results of a Phase II Study

2012 711 citations Barbara Pro, Ranjana H. Advani et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Dana A. Kennedy United States	24	3.0k	2.8k	929	891	887	50	4.5k
Radhakrishnan Ramchandren United States	26	3.2k 1.1×	3.1k 1.1×	582 0.6×	551 0.6×	977 1.1×	88	4.6k
Robert Chen United States	31	3.1k 1.0×	3.4k 1.2×	416 0.4×	555 0.6×	963 1.1×	81	4.7k
Michelle A. Fanale United States	36	4.1k 1.4×	3.9k 1.4×	734 0.8×	649 0.7×	1.4k 1.5×	252	6.4k
Rita M. Braziel United States	37	2.7k 0.9×	1.6k 0.6×	616 0.7×	416 0.5×	668 0.8×	99	4.3k
Mukesh Chhanabhai Canada	28	4.8k 1.6×	2.9k 1.0×	821 0.9×	303 0.3×	1.0k 1.1×	48	5.6k
Maurizio Bendandi Italy	41	2.4k 0.8×	1.9k 0.7×	334 0.4×	578 0.6×	1.9k 2.2×	112	4.7k
Andrei R. Shustov United States	34	3.3k 1.1×	2.5k 0.9×	1.4k 1.5×	311 0.3×	2.0k 2.2×	158	5.3k
Steven M. Horwitz United States	42	4.8k 1.6×	3.1k 1.1×	1.5k 1.6×	404 0.5×	2.1k 2.3×	239	7.0k
Harald Stein Germany	33	1.9k 0.6×	1.5k 0.5×	467 0.5×	548 0.6×	1.1k 1.3×	53	4.0k
Lapo Alinari United States	30	1.7k 0.6×	793 0.3×	442 0.5×	487 0.5×	518 0.6×	115	2.8k

Countries citing papers authored by Dana A. Kennedy

Since Specialization

Citations

This map shows the geographic impact of Dana A. Kennedy's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Dana A. Kennedy with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Dana A. Kennedy more than expected).

Fields of papers citing papers by Dana A. Kennedy

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Dana A. Kennedy. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Dana A. Kennedy. The network helps show where Dana A. Kennedy may publish in the future.

Co-authorship network of co-authors of Dana A. Kennedy

This figure shows the co-authorship network connecting the top 25 collaborators of Dana A. Kennedy. A scholar is included among the top collaborators of Dana A. Kennedy based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Dana A. Kennedy. Dana A. Kennedy is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Fizazi, Karim, Arun Azad, Nobuaki Matsubara, et al.. (2025). Talazoparib plus enzalutamide in men with HRR-deficient metastatic castration-resistant prostate cancer: final overall survival results from the randomised, placebo-controlled, phase 3 TALAPRO-2 trial. The Lancet. 406(10502). 461–474. 1 indexed citations

Agarwal, Neeraj, Arun Azad, Joan Carles, et al.. (2025). Final overall survival (OS) with talazoparib (TALA) + enzalutamide (ENZA) as first-line treatment in unselected patients with metastatic castration-resistant prostate cancer (mCRPC) in the phase 3 TALAPRO-2 trial.. Journal of Clinical Oncology. 43(5_suppl). 11 indexed citations

Gopal, Ajay K., Barbara Pro, Joseph M. Connors, et al.. (2016). Response assessment in lymphoma: Concordance between independent central review and local evaluation in a clinical trial setting. Clinical Trials. 13(5). 545–554.

Illidge, Tim, Barbara Pro, Lorenz Trümper, et al.. (2014). Phase 3 Trial of Brentuximab Vedotin and Chp Versus Chop in the Frontline Treatment of Patients (Pts) with Cd30+ Mature T-Cell Lymphomas (Mtcl). Annals of Oncology. 25. iv338–iv338. 2 indexed citations

Stein, Eytan M., Anthony S. Stein, Roland B. Walter, et al.. (2014). Interim Analysis of a Phase 1 Trial of SGN-CD33A in Patients with CD33-Positive Acute Myeloid Leukemia (AML). Blood. 124(21). 623–623. 26 indexed citations

Younes, Anas, Ajay K. Gopal, Scott E. Smith, et al.. (2012). Results of a Pivotal Phase II Study of Brentuximab Vedotin for Patients With Relapsed or Refractory Hodgkin's Lymphoma. Journal of Clinical Oncology. 30(18). 2183–2189. 1014 indexed citations breakdown →

Forero‐Torres, Andres, Michelle A. Fanale, Ranjana H. Advani, et al.. (2012). Brentuximab Vedotin in Transplant-Naïve Patients with Relapsed or Refractory Hodgkin Lymphoma: Analysis of Two Phase I Studies. The Oncologist. 17(8). 1073–1080. 34 indexed citations

Fromm, Jonathan R., et al.. (2012). Clinical Binding Properties, Internalization Kinetics, and Clinicopathologic Activity of Brentuximab Vedotin: An Antibody-Drug Conjugate for CD30-Positive Lymphoid Neoplasms. Clinical Lymphoma Myeloma & Leukemia. 12(4). 280–283. 25 indexed citations

Fanale, Michelle A., Andrei R. Shustov, Andres Forero‐Torres, et al.. (2012). Brentuximab Vedotin Administered Concurrently with Multi-Agent Chemotherapy As Frontline Treatment of ALCL and Other CD30-Positive Mature T-Cell and NK-Cell Lymphomas. Blood. 120(21). 60–60. 25 indexed citations

10.

Shustov, Andrei R., Joseph D. Rosenblatt, Dana A. Kennedy, & Michelle A. Fanale. (2012). Peripheral Blood Stem Cell (PBSC) Mobilization and Engraftment after Brentuximab Vedotin Treatment in Anaplastic Large Cell Lymphoma (ALCL) Patients. Annals of Oncology. 23. ix353–ix354. 2 indexed citations

11.

Fanale, Michelle A., Andres Forero‐Torres, Joseph D. Rosenblatt, et al.. (2011). A Phase I Weekly Dosing Study of Brentuximab Vedotin in Patients with Relapsed/Refractory CD30-Positive Hematologic Malignancies. Clinical Cancer Research. 18(1). 248–255. 160 indexed citations

12.

Smith, Scott E., Steven M. Ansell, Joseph D. Rosenblatt, et al.. (2011). Results from a pivotal phase II study of brentuximab vedotin (SGN-35) in patients with relapsed or refractory Hodgkin lymphoma (HL).. Journal of Clinical Oncology. 29(15_suppl). 8031–8031. 31 indexed citations

13.

Pro, Barbara, Ranjana H. Advani, Pauline Brice, et al.. (2011). Durable remissions with brentuximab vedotin (SGN-35): Updated results of a phase II study in patients with relapsed or refractory systemic anaplastic large cell lymphoma (sALCL).. Journal of Clinical Oncology. 29(15_suppl). 8032–8032. 22 indexed citations

14.

Shustov, Andrei R., Ranjana H. Advani, Pauline Brice, et al.. (2010). Complete Remissions with Brentuximab Vedotin (SGN-35) in Patients with Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma. Blood. 116(21). 961–961. 27 indexed citations

15.

Younes, Anas, Nancy L. Bartlett, John P. Leonard, et al.. (2010). Brentuximab Vedotin (SGN-35) for Relapsed CD30-Positive Lymphomas. New England Journal of Medicine. 363(19). 1812–1821. 963 indexed citations breakdown →

16.

Duvic, Madeleine, Sunil Reddy, Lauren Pinter‐Brown, et al.. (2009). A Phase II Study of SGN-30 in Cutaneous Anaplastic Large Cell Lymphoma and Related Lymphoproliferative Disorders. Clinical Cancer Research. 15(19). 6217–6224. 61 indexed citations

17.

Fanale, Michelle A., Nancy L. Bartlett, Andres Forero‐Torres, et al.. (2009). The Antibody-Drug Conjugate Brentuximab Vedotin (SGN-35) Induced Multiple Objective Responses in Patients with Relapsed or Refractory CD30-Positive Lymphomas in a Phase 1 Weekly Dosing Study.. Blood. 114(22). 2731–2731. 24 indexed citations

18.

Bartlett, Nancy L., Andres Forero‐Torres, Joseph D. Rosenblatt, et al.. (2009). Complete remissions with weekly dosing of SGN-35, a novel antibody-drug conjugate (ADC) targeting CD30, in a phase I dose-escalation study in patients with relapsed or refractory Hodgkin lymphoma (HL) or systemic anaplastic large cell lymphoma (sALCL). Journal of Clinical Oncology. 27(15_suppl). 8500–8500. 24 indexed citations

19.

Forero‐Torres, Andres, John P. Leonard, Anas Younes, et al.. (2009). A Phase II study of SGN‐30 (anti‐CD30 mAb) in Hodgkin lymphoma or systemic anaplastic large cell lymphoma. British Journal of Haematology. 146(2). 171–179. 192 indexed citations

20.

Kennedy, Dana A., et al.. (1981). Prevalence of hepatitis B markers in Indochinese refugees.. PubMed. 125(11). 1243–6. 20 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact